Share Email Print

Proceedings Paper

Long-term effects of laser-imiquimod combination in the treatment of late-stage melanoma patients
Author(s): Mark F. Naylor; Henry Le; Xiaosong Li; Robert E. Nordquist; Tomas Hode; Hong Liu; Wei R. Chen
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Topical application of a potent immunological modulator, imiquimod, followed by laser irradiation has been used for the treatment of late-stage melanoma patients. This novel approach, laser-assisted laser immunotherapy (LIT), targets the root course of melanoma, a highly metastatic cancer. We started a phase I clinical trial in 2006 with promising initial outcomes. The laser-imiquimod combination showed significant palliative effects for these patients with multiple treatment cycles. For the returning patients, we found that the recurrent tumors were less aggressive than usually seen in untreated patients. The current protocol uses a light-absorbing dye for selective laser photothermal interaction with a non-invasive treatment mode. It has limitations for patient treatment, particularly for large, deeper tumors, and for patients with dark pigmented skins. This study provides some information on the treated patients (both stage IV and stage IV) during the past several years. We also discuss the future directions of LIT, particularly in the area of photothermal treatment mode with a new approach of interstitial irradiation. The current results in melanoma treatment using LIT indicate that the combination of photothermal therapy and immunological stimulation may hold the key for the treatment of late-stage, metastatic cancers, not only for cutaneous cancers such as melanoma and breast cancer, but also for deep and internal tumors using different operations modes such as interstitial laser irradiation.

Paper Details

Date Published: 9 February 2012
PDF: 8 pages
Proc. SPIE 8224, Biophotonics and Immune Responses VII, 822406 (9 February 2012); doi: 10.1117/12.906568
Show Author Affiliations
Mark F. Naylor, Dermatology Associates of San Antonio (United States)
Henry Le, Univ. of Central Oklahoma (United States)
Xiaosong Li, First Affiliated Hospital of Chinese PLA (China)
Chinese PLA General Hospital (China)
Robert E. Nordquist, The Univ. of Oklahoma (United States)
Tomas Hode, The Univ. of Oklahoma (United States)
Hong Liu, Immunophotonics, Inc. (United States)
Wei R. Chen, Dermatology Associates of San Antonio (United States)

Published in SPIE Proceedings Vol. 8224:
Biophotonics and Immune Responses VII
Wei R. Chen, Editor(s)

© SPIE. Terms of Use
Back to Top